Douglas J. Williamson - 29 Jul 2026 Form 4 Insider Report for Vistagen Therapeutics, Inc. (VTGN)

Reporting relationship: Director
Issuer ticker: VTGN
Reported as of: 29 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Jul 2026, 08:56:25 UTC
Prior SEC filing: 13 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Douglas J. Williamson

Key filing fact

Douglas J. Williamson filed Form 4 for Vistagen Therapeutics, Inc. (VTGN) on 31 Jul 2026.

Key facts

This page summarizes Douglas J. Williamson's Form 4 filing for Vistagen Therapeutics, Inc. (VTGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Jul 2026, 08:56.

Change

Previous filing in this sequence was filed on 13 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001911501 Primary reporting owner

Williamson Douglas J

Relationship: Director
Address: C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Signature: /s/ Douglas J. Williamson
Signature date: 31 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VTGN transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +40,826
Change %
Price: $0.000000^*
Shares after: 40,826
Date: 29 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,826
Exercise price: $0.2433
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant.